Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 19, 2006, Pages 5018-5021

  Zheng, Guangrong ^a   Horton, David B ^a   Deaciuc, Agripina G ^a   Dwoskin, Linda P ^a   Crooks, Peter A ^a  

^a University of Kentucky   (United States)

Author keywords

Dopamine transporter; Lobeline; Serotonin transporter; Vesicular monoamine transporter

Indexed keywords

DOPAMINE TRANSPORTER; LOBELINE; NICOTINIC RECEPTOR; SEROTONIN TRANSPORTER;

ARTICLE; CELL VACUOLE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; RECEPTOR AFFINITY; SCREENING; SYNAPSE;

DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LOBELINE; PROTEIN BINDING; RECEPTORS, NICOTINIC; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 33747340517     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.070     Document Type: Article

References (24)

1. Hyttel J. Int. Clin. Psychopharmacol. 1 (1994) 19
2. Schloss P., and Williams D.C. J. Psychopharmacol. 12 (1998) 115
3. Owens M.J., and Nemeroff C.B. Depression Anxiety 8 (1998) 5
4. White K.J., Walline C.C., and Barker E.L. AAPS J. 7 (2005) E421
5. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E., and Sulser F. J. Clin. Psychiatry 56 (1995) 395
6. Frazer A. J. Clin. Psychiatry 61 (2000) 25
7. Massana J., Moller H.J., Burrows G.D., and Montenegro R.M. Int. Clin. Psychopharmacol. 14 (1999) 73
8. Jankovic J., and Beach J. Neurology 48 (1997) 358
9. Kenney C., and Jankovic J. Expert Rev. Neurother. 6 (2006) 7
10. Newman A.H. Expert Opin. Ther. Pat. 10 (2000) 1095
11. Carroll F.I., Lewin A.H., and Marscarella S.W. In: Reith M.E. (Ed). Neurotransmitter Transporters: Structure, Function and Regulation (2002), Humana Press, Totowa, NJ 381
12. Carroll F.I. J. Med. Chem. 46 (2003) 1775
13. Miller D.K., Crooks P.A., and Dwoskin L.P. Neuropharmacology 39 (2000) 2654
14. Briggs C.A., and McKenna D.G. Mol. Pharmacol. 54 (1998) 1095
15. Miller D.K., Crooks P.A., Zheng G., Grinevich V.P., Norrholm S., and Dwoskin L.P. J. Pharmacol. Exp. Ther. 310 (2004) 1035
16. Dwoskin L.P., and Crooks P.A. Biochem. Pharmacol. 63 (2002) 89
17. Teng L., Crooks P.A., Sonsalla P.K., and Dwoskin L.P. J. Pharmacol. Exp. Ther. 280 (1997) 1432
18. Teng L., Crooks P.A., and Dwoskin L.P. J. Neurochem. 71 (1998) 258
19. 2O: C, 72.21; H, 8.45; N, 3.83. Found: C, 72.05; H, 8.71; N, 4.06.
20. Flammia D., Malgorzata D., Damaj M.I., Martin B., and Glennon R.A. J. Med. Chem. 42 (1999) 3726
21. Ebnöther A. Helv. Chim. Acta 41 (1958) 386
22. Fuller R.W., Wong D.T., and Robertson D.W. Med. Res. Rev. 11 (1991) 17
23. Lee L.C., Vander Borght T., Sherman P.S., Frey K.A., and Kilbourn M.R. J. Med. Chem. 39 (1996) 191
24. Zheng G., Dwoskin L.P., Deaciuc A.G., Norrholm S.D., and Crooks P.A. J. Med. Chem. 48 (2005) 5551